Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Jan 1;21(1):546-9.
doi: 10.1016/j.bmcl.2010.10.074. Epub 2010 Nov 17.

Antitumor agents 281. Design, synthesis, and biological activity of substituted 4-amino-7,8,9,10-tetrahydro-2H-benzo[h]chromen-2-one analogs (ATBO) as potent in vitro anticancer agents

Affiliations

Antitumor agents 281. Design, synthesis, and biological activity of substituted 4-amino-7,8,9,10-tetrahydro-2H-benzo[h]chromen-2-one analogs (ATBO) as potent in vitro anticancer agents

Yizhou Dong et al. Bioorg Med Chem Lett. .

Abstract

In our exploration of new biologically active chemical entities, we designed and synthesized a novel class of antitumor agents, substituted 4-amino-7,8,9,10-tetrahydro-2H-benzo[h]chromen-2-one (ATBO) analogs. We evaluated their cytotoxic activity against seven human tumor cell lines from different tissues, and established preliminary structure-activity relationships (SAR). All analogs, except 8, 9, and 25-27, displayed potent tumor cell growth inhibitory activity. Especially, compounds 15 and 33 with a 4-methoxyphenyl group at position C-4 were extremely potent with ED(50) values of 0.008-0.064 and 0.035-0.32 μM, respectively. Compound 15 was the most potent analog compared with structurally related neo-tanshinlactone (e.g., 1) and 4-amino-2H-benzo[h]chromen-2-one (ABO, e.g., 4) analogs, and thus merits further exploration as an anti-cancer drug candidate.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Structures of neo-tanshinlactone (1), 4-ethyl neo-tanshinlactone (2), previously reported scaffold 3 and its analog 4, and newly designed scaffold 5
Scheme 1
Scheme 1
Reagents and conditions: (a) POCl3, Et3N, reflux, 1h; (b) aliphatic amines, EtOH, reflux, 2h; (c) aromatic amines, ethylene glycol, 160 °C, 1h.

Similar articles

Cited by

References

    1. Bleicher Konrad H, Bohm H-J, Muller K, Alanine Alexander I. Hit and lead generation: beyond high-throughput screening. Nat Rev Drug Discov. 2003;2:369–78. - PubMed
    1. Vallance P, Williams P, Dollery C. The future is much closer collaboration between the pharmaceutical industry and academic medical centers. Clin Pharmacol Ther. 87:525–7. - PubMed
    1. Hughes B. FDA drug approvals. Nat Rev Drug Discov. 2009;9:89–92. - PubMed
    1. Crommelin D, Stolk P, Besancon L, Shah V, Midha K, Leufkens H. Pharmaceutical sciences in 2020. Nat Rev Drug Discov. 9:99–100. - PubMed
    1. Wang X, Bastow KF, Sun CM, Lin YL, Yu HJ, Don MJ, Wu TS, Nakamura S, Lee KH. Antitumor Agents. 239. Isolation, structure elucidation, total synthesis, and anti-breast cancer activity of neo-tanshinlactone from Salvia miltiorrhiza. J Med Chem. 2004;47:5816–9. - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources